Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024

Rhea-AI Summary

Galmed Pharmaceuticals (NASDAQ: GLMD), a clinical-stage biopharmaceutical company specializing in liver, cardiometabolic diseases and GI oncological indications, has announced the filing of its Annual Report on Form 20-F for the fiscal year ended December 31, 2024, with the U.S. Securities and Exchange Commission.

The report is accessible on both the SEC website and Galmed's Investor Relations platform. Shareholders can request free copies of the annual report through the company's Investor Relations Department.

Argus Session date unavailable

-2.67% session move Open Argus

Details

News Market Reaction – GLMD

The recorded move for GLMD in the trading session of this news was -2.67%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

TEL AVIV, Israel, April 2, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ('Galmed' or the 'Company'), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic diseases and GI oncological indications, today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2024, with the U.S. Securities and Exchange Commission (the 'SEC').

The report is available on the SEC's website, at www.sec.gov and Galmed's Investor Relations website, at https://galmedpharma.investorroom.com/sec-filings.

Shareholders can obtain copies of Galmed's Annual Report on Form 20-F, free of charge, by making a request within a reasonable period of time to Galmed's Investor Relations Department at investor.relations@galmedpharma.com.

About Galmed Pharmaceuticals Ltd.

We are a clinical stage biopharmaceutical company focused on the development of Aramchol for oncological indications outside of liver disease. In addition, as part of our growth strategy, we are actively pursuing opportunities to expand and diversify our product pipeline specifically targeting cardiometabolic indications and other innovative product candidates that align with our core expertise in drug development.

Forward-Looking Statements:

Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to our objectives plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that we intend, expect, project, believes or anticipate will or may occur in the future. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to the development and approval of the use of Aramchol or any other product candidate for indications outside of NASH and fibrosis or in combination therapy; the timing and cost of any pre-clinical or clinical trials of Aramchol or any other product candidate we develop; completion and receiving favorable results of any pre-clinical or clinical trial; regulatory action with respect to Aramchol or any other product candidate by the U.S. Food and Drug Administration or the European Medicines Authority, including but not limited to acceptance of an application for marketing authorization, review and approval of such application, and, if approved, the scope of the approved indication and labeling; the commercial launch and future sales of Aramchol and any future product candidates; our ability to comply with all applicable post-market regulatory requirements for Aramchol, or any other product candidate in the countries in which we seek to market the product; our ability to achieve favorable pricing for Aramchol, or any other product candidate; third-party payor reimbursement for Aramchol, or any other product candidate; our estimates regarding anticipated capital requirements and our needs for additional financing; market adoption of Aramchol or any other product candidate by physicians and patients; the timing, cost or other aspects of the commercial launch of Aramchol or any other product candidate; our ability to obtain and maintain adequate protection of our intellectual property; the possibility that we may face third-party claims of intellectual property infringement; our ability to manufacture our product candidates in commercial quantities, at an adequate quality or at an acceptable cost; our ability to establish adequate sales, marketing and distribution channels; intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do; our expectations regarding licensing, acquisitions and strategic operations; current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk; our ability to maintain the listing of our ordinary shares on The Nasdaq Capital Market; and the security, political and economic instability in the Middle East that could harm our business, including due to the current security situation in Israel. We believe these forward-looking statements are reasonable; however, these statements are only current predictions and are subject to known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements. We discuss many of these risks in our Annual Report on Form 20-F for the year ended December 31, 2024 filed with the SEC on April 2, 2025 in greater detail under the heading "Risk Factors." Given these uncertainties, you should not rely upon forward-looking statements as predictions of future events. All forward-looking statements attributable to us or persons acting on our behalf speak only as of the date hereof and are expressly qualified in their entirety by the cautionary statements included in this report. We undertake no obligations to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events. In evaluating forward-looking statements, you should consider these risks and uncertainties.

Logo: https://mma.prnewswire.com/media/1713483/Galmed_Pharmaceuticals_Logo.jpg

 

View original content:https://www.prnewswire.com/news-releases/galmed-pharmaceuticals-ltd-files-annual-report-on-form-20-f-for-the-fiscal-year-ended-december-31-2024-302418921.html

SOURCE Galmed Pharmaceuticals Ltd.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When did Galmed Pharmaceuticals (GLMD) file its 2024 Annual Report?

Galmed Pharmaceuticals filed its Annual Report on Form 20-F for fiscal year 2024 on April 2, 2025.

Where can investors access Galmed Pharmaceuticals' (GLMD) 2024 Annual Report?

The report is available on the SEC's website (www.sec.gov) and Galmed's Investor Relations website.

How can shareholders obtain copies of Galmed Pharmaceuticals' (GLMD) 2024 Annual Report?

Shareholders can request free copies by contacting Galmed's Investor Relations Department at investor.relations@galmedpharma.com.

What are the main therapeutic areas of focus for Galmed Pharmaceuticals (GLMD)?

Galmed focuses on liver, cardiometabolic diseases and GI oncological indications.